QIAGEN N.V. (NYSE:QGEN) Receives $49.69 Average Target Price from Brokerages

QIAGEN N.V. (NYSE:QGEN) has earned an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $49.6865.

QGEN has been the topic of several research analyst reports. Cowen reissued a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Barclays initiated coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They set an “overweight” rating and a $55.00 target price on the stock. Bank of America raised their target price on shares of QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, June 26th. Wall Street Zen cut shares of QIAGEN from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 11th. Finally, UBS Group lifted their price objective on shares of QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th.

QIAGEN Trading Up 0.7%

Shares of NYSE:QGEN opened at $45.75 on Tuesday. The company has a market cap of $10.17 billion, a PE ratio of 27.03, a P/E/G ratio of 2.40 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The company’s 50-day moving average price is $48.27 and its 200 day moving average price is $44.78. QIAGEN has a fifty-two week low of $37.63 and a fifty-two week high of $51.88.

QIAGEN (NYSE:QGEN) last released its earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analysts’ expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. QIAGEN’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company earned $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Sell-side analysts anticipate that QIAGEN will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On QIAGEN

Several hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. grew its stake in shares of QIAGEN by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after purchasing an additional 1,951 shares during the last quarter. Orion Porfolio Solutions LLC increased its position in shares of QIAGEN by 120.6% in the second quarter. Orion Porfolio Solutions LLC now owns 29,361 shares of the company’s stock worth $1,411,000 after acquiring an additional 16,054 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of QIAGEN by 11.4% in the second quarter. Squarepoint Ops LLC now owns 13,548 shares of the company’s stock worth $651,000 after acquiring an additional 1,386 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of QIAGEN by 57.5% in the second quarter. Neuberger Berman Group LLC now owns 30,478 shares of the company’s stock worth $1,463,000 after acquiring an additional 11,126 shares in the last quarter. Finally, Pitcairn Co. purchased a new position in shares of QIAGEN in the second quarter worth approximately $208,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.